Pursuant to Regulation 30 read with Clause 7 of Para A of Part A of Schedule Ill of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Abbott India has informed that Kunal Chowdhury - Commercial Director - GI Businesses has been promoted to another affiliate of the company effective February 1, 2025. He will serve his role as Commercial Director - GI Businesses with the company until January 31, 2025. Pursuant to the above, he will also cease to be the Senior Management Personnel of the Company effective close of business hours of January 31, 2025. The details required to be disclosed as per SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 is enclosed.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1779.40 |
| Dr. Reddys Lab | 1268.75 |
| Cipla | 1376.75 |
| Zydus Lifesciences | 1105.75 |
| Lupin | 2263.40 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: